Metabolic memory in diabetes is true long-term memory

Archives of Ophthalmology

Volumn 127, Issue 3, 2009, Pages 330-331

  Frank, Robert N ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE CONTROL; DISEASE COURSE; EDITORIAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LONG TERM MEMORY; MEDICAL RESEARCH; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA;

BLOOD GLUCOSE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HOMEOSTASIS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 62549138756     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2008.607     Document Type: Editorial

References (18)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
3. DCCT/Epidemiology of Diabetes Interventions and Complications Research Group. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes: 10 years after the DCCT. Arch Ophthalmol. 2008;126(12):1707-1715.
4. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287(19):2563-2569.
5. The DCCT/EDIC group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16):2159-2167.
6. Martin CL, Albers J, Herman WH, et al; DCCT/EDIC Research Group. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006;29(2):340-344.
7. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes. 1987;36(7):808-812.
8. Engerman RL, Kern TS. Retinopathy in galactosemic dogs continues to progress after cessation of galactosemia. Arch Ophthalmol. 1994;113:355-358.
9. Caird FI, Pirie A, Ramsell TG. Diabetes and the Eye. Oxford, England: Blackwell; 1969.
10. Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci U S A. 1990;87(1):404-408.
11. Genuth S, Sun W, Cleary P, et al; DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 2005;54(11):3103-3111.
12. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, II: prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102(4):520-526.
13. Nelson RG, Knowler WC, Pettitt DJ, Bennett PH. Kidney diseases in diabetes. In: Diabetes in America. 2nd ed. Washington, DC: National Diabetes Data Group, National Institute of Diabetes, Digestive and Kidney Diseases, US National Institutes of Health; 1995:349-400.
14. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989;320(18):1161-1165.
15. The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes. 1997;46(11):1829-1839.
16. Al-Kateb H, Mirea L, Xie X, et al; DCCT/EDIC Research Group. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. Diabetes. 2007;56(8):2161-2168.
17. Al-Kateb H, Boright AP, Mirea L, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes. 2008;57(1):218-228.
18. Tong Z, Yang Z, Patel S, et al; Genetics of Diabetes and Diabetic Complication Study Group. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A. 2008;105(19):6998-7003.